Lilly Phase 3b data: Taltz with Zepbound improves efficacy in psoriatic arthritis and obesity
FROM THE WIRE · FINANCE.YAHOO.COM
Nearly three times as many patients taking Taltz and Zepbound achieved ≥50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind TOGETHER-PsA study Improvements in disease activity at one year follow statistically…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive one-year results for a new combined use of two Lilly drugs, relevant to the company's portfolio.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Nearly three times as many patients reached ACR50 at one year with Taltz and Zepbound versus Taltz alone.
- 02The TOGETHER-PsA study is an open-label Phase 3b trial.
- 03Detailed data were presented at ACR Convergence 2026 and published in Arthritis & Rheumatology.
- 04The 52-week results show durable efficacy and metabolic outcomes.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets